Mark E. Rempala

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F

Liandong Ma, Joshua R. Clayton, Richard A. Walgren et al. · Blood Cancer Journal · 2013 · 66 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

Timothy P. Burkholder, Joshua R. Clayton, Mark E. Rempala et al. · Investigational New Drugs · 2011 · 17 citations

Medicine, Oncology, Pharmacology +15

Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT

Saravanan Parthasarathy, Kenneth J. Henry, Huaxing Pei et al. · Bioorganic & Medicinal Chemistry Letters · 2018 · 17 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +7